Purine Nucleoside Analog - Sulfinosine Modulates Diverse Mechanisms of Cancer Progression in Multi-Drug Resistant Cancer Cell Lines

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Dačević, Mirjana ^a   Isaković, Aleksandra ^a   Podolski Renić, Ana ^a   Isaković, Andelka M ^a   Stanković, Tijana ^a   Milošević, Zorica ^a   Rakić, Ljubisav ^b   Ruždijić, Sabera ^a   Pešić, Milica ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b SERBIAN ACADEMY OF SCIENCES AND ARTS   (Serbia)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; DOXORUBICIN; GLUTAMATE CYSTEINE LIGASE; GLUTATHIONE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; PURINE NUCLEOSIDE DERIVATIVE; REACTIVE OXYGEN METABOLITE; SULFINOSINE; TARIQUIDAR; VASCULOTROPIN; VERAPAMIL;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER CELL; CANCER INHIBITION; CANCER RESISTANCE; CELL HYPOXIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG SENSITIVITY; DRUG STRUCTURE; GENE EXPRESSION; HUMAN; HUMAN CELL; KERATINOCYTE; MULTIDRUG RESISTANCE; PROTEIN SECRETION;

APOPTOSIS; AUTOPHAGY; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; GLUTAMATE-CYSTEINE LIGASE; GLUTATHIONE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; P-GLYCOPROTEIN; PURINE NUCLEOSIDES; REACTIVE OXYGEN SPECIES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84872229958     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0054044     Document Type: Article

References (44)

1. Revankar GR, Hanna NB, Imamura N, Lewis AF, Larson SB, et al. (1990) Synthesis and in vivo antitumor activity of 2-amino-9H-purine-6-sulfenamide,-sulfinamide, and-sulfonamide and related purine ribonucleosides. J Med Chem 33: 121-128.
2. Avery TL, Finch RA, Vasquez KM, Radparvar S, Hanna NB, et al. (1990) Chemotherapeutic characterization in mice of 2-amino-9-beta-D-ribofuranosylpurine-6-sulfinamide (sulfinosine), a novel purine nucleoside with unique antitumor properties. Cancer Res 50: 2625-2630.
3. Bosch TM, Meijerman I, Beijnen JH, Schellens JH, (2006) Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer. Clin Pharmacokinet 45: 253-285.
4. Presta M, Belleri M, Vacca A, Ribatti D, (2002) Anti-angiogenic activity of the purine analog 6-thioguanine. Leukemia 16: 1490-1499.
5. Pesić M, Andjelković T, Banković J, Marković ID, Rakić L, et al. (2009) Sulfinosine enhances doxorubicin efficacy through synergism and by reversing multidrug resistance in the human non-small cell lung carcinoma cell line (NCI-H460/R). Invest New Drugs 27: 99-110.
6. Andjelkovic T, Pesic M, Bankovic J, Tanic N, Markovic ID, et al. (2008) S: Synergistic effects of the purine analog sulfinosine and curcumin on the multidrug resistant human non-small cell lung carcinoma cell line (NCI-H460/R). Cancer Biol Ther 7: 1024-1032.
7. Pesić M, Podolski A, Rakić L, Ruzdijić S, (2010) Purine analogs sensitize the multidrug resistant cell line (NCI-H460/R) to doxorubicin and stimulate the cell growth inhibitory effect of verapamil. Invest New Drugs 28: 482-492.
8. Nobili S, Landini I, Mazzei T, Mini E (2011) Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression. Med Res Rev, doi:10.1002/med.20239.
9. Pesic M, Markovic JZ, Jankovic D, Kanazir S, Markovic ID, et al. (2006) Induced resistance in the human non small cell lung carcinoma (NCI-H460) cell line in vitro by anticancer drugs. J Chemother 18: 66-73.
10. Podolski-Renić A, Andelković T, Banković J, Tanić N, Ruždijić S, et al. (2011) The role of paclitaxel in the development and treatment of multidrug resistant cancer cell lines. Biomed Pharmacother 65: 345-353.
11. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, et al. (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82: 1107-1112.
12. Kang W, Nielsen O, Fenger C, Leslie G, Holmskov U, et al. (2005) Induction of DMBT1 expression by reduced ERK activity during a gastric mucosa differentiation-like process and its association with human gastric cancer. Carcinogenesis 26: 1129-1137.
13. O'Driscoll L, Daly C, Saleh M, Clynes M, (1993) The use of reverse transcriptase-polymerase chain reaction (RT-PCR) to investigate specific gene expression in multidrug-resistant cells. Cytotechnology 12: 289-314.
14. Harada H, Nakagawa K, Iwata S, Saito M, Kumon Y, et al. (1999) Restoration of wild-type p16 down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human gliomas. Cancer Res 59: 3783-3789.
15. Bosch S, Siavoshian S, Jacquot C, Tomasoni C, Dabouis G, et al. (1997) Correlation between multidrug resistance and the degree of differentiation of non-small-cell bronchopulmonary carcinoma (NSCLC) in vitro and in vivo. Anticancer Res 17: 4595-4598.
16. Nardinocchi L, Puca R, Sacchi A, D'Orazi G, (2009) Inhibition of HIF-1alpha activity by homeodomain-interacting protein kinase-2 correlates with sensitization of chemoresistant cells to undergo apoptosis. Mol Cancer 8: 1.
17. NicAmhlaoibh R, Heenan M, Cleary I, Touhey S, O'Loughlin C, et al. (1999) Altered expression of mRNAs for apoptosis-modulating proteins in a low level multidrug resistant variant of a human lung carcinoma cell line that also expresses mdr1 mRNA. Int J Cancer 82: 368-376.
18. Wong H, Anderson WD, Cheng T, Riabowol KT, (1994) Monitoring mRNA expression by polymerase chain reaction: the "primer-dropping" method. Anal Biochem 223: 251-258.
19. Walbert T, Gilbert MR, Groves MD, Puduvalli VK, Yung WK, et al. (2011) Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma. J Neurooncol 102: 273-280.
20. Taylor RC, Cullen SP, Martin SJ, (2008) Apoptosis: controlled demolition at the cellular level. Nat Rev Mol Cell Biol 9: 231-241.
21. Xu Y, (2008) Induction of genetic instability by gain-of-function p53 cancer mutants. Oncogene 27: 3501-3507.
22. Fujitaki JM, Nord LD, Willis RC, (1989) Cellular metabolism of the antitumor nucleoside, sulfinosine, 2-amino-9-(β-D-ribofuranosyl) purine-6-sulfinamide. Proc Am Assoc Cancer Res 30: 596.
23. Riley TA, Finch RA, Vasquez KM, (1989) Isolation, identification, synthesis and therapeutic evaluation of selected metabolites of sulfinosine a novel purine nucleoside analog active against thiopurine refractory experimental leukemia. Proc Am Assoc Cancer Res 30: 599.
24. Rudin CM, Yang Z, Schumaker LM, VanderWeele DJ, Newkirk K, et al. (2003) Inhibition of glutathione synthesis reverses Bcl-2-mediated cisplatin resistance. Cancer Res 63: 312-318.
25. Ghibelli L, Coppola S, Fanelli C, Rotilio G, Civitareale P, et al. (1999) Glutathione depletion causes cytochrome c release even in the absence of cell commitment to apoptosis. FASEB J 13: 2031-2036.
26. Chang CY, Shen CC, Su HL, Chen CJ (2011) Gefitinib induces apoptosis in human glioma cells by targeting Bad phosphorylation. J Neurooncol. doi:10.1007/s11060-011-0632-3.
27. Li G, Xu Y, Guan D, Liu Z, Liu DX, (2011) HSP70 protein promotes survival of C6 and U87 glioma cells by inhibition of ATF5 degradation. J Biol Chem 286: 20251-20259.
28. Voss V, Senft C, Lang V, Ronellenfitsch MW, Steinbach JP, et al. (2010) The pan-Bcl-2 inhibitor (-)-gossypol triggers autophagic cell death in malignant glioma. Mol Cancer Res 8: 1002-1016.
29. Eimer S, Belaud-Rotureau MA, Airiau K, Jeanneteau M, Laharanne E, et al. (2011) Autophagy inhibition cooperates with erlotinib to induce glioblastoma cell death. Cancer Biol Ther 11: 1017-1027.
30. Maiuri MC, Zalckvar E, Kimchi A, Kroemer G, (2007) Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol 8: 741-752.
31. Menon SG, Goswami PC, (2007) A redox cycle within the cell cycle: ring in the old with the new. Oncogene 26: 1101-1109.
32. Zhao H, Kalivendi S, Zhang H, Joseph J, Nithipatikom K, et al. (2003) Superoxide reacts with hydroethidine but forms a fluorescent product that is distinctly different from ethidium: potential implications in intracellular fluorescence detection of superoxide. Free Radic Biol Med 34: 1359-1368.
33. Townsend DM, Tew KD, Tapiero H, (2003) The importance of glutathione in human disease. Biomed. Pharmacother 57: 145-155.
34. Sokoloski JA, Sartorelli AC, (1987) Inhibition of the synthesis of glycoproteins and induction of the differentiation of HL-60 promyelocytic leukemia cells by 6-methylmercaptopurine ribonucleoside. Cancer Res 47: 6283-6287.
35. Fontanini G, Vignati S, Boldrini L, Chinè S, Silvestri V, et al. (1997) Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma. Clin Cancer Res 3: 861-865.
36. Jansen M, de Witt Hamer PC, Witmer AN, Troost D, van Noorden CJ, (2004) Current perspectives on antiangiogenesis strategies in the treatment of malignant gliomas. Brain Res Rev 45: 143-163.
37. Horn L, Sandler AB, (2009) Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer. Clin Lung Cancer 10: S7-16.
38. Underiner TL, Ruggeri B, Gingrich DE, (2004) Development of vascular endothelial growth factor receptor (VEGFR) kinase inhibitors as anti-angiogenic agents in cancer therapy. Curr Med Chem 11: 731-745.
39. Jin WS, Kong ZL, Shen ZF, Jin YZ, Zhang WK, et al. (2011) Regulation of hypoxia inducible factor-1α expression by the alteration of redox status in HepG2 cells. J Exp Clin Cancer Res 30: 61.
40. Dunne G, Breen L, Collins DM, Roche S, Clynes M, et al. (2011) Modulation of P-gp expression by lapatinib. Invest New Drugs 29: 1284-1293.
41. Hawkins BT, Sykes DB, Miller DS, (2010) Rapid, reversible modulation of blood-brain barrier P-glycoprotein transport activity by vascular endothelial growth factor. J Neurosci 30: 1417-1425.
42. Gridelli C, Rossi A, Maione P, (2003) Treatment of non-small-cell lung cancer: state of the art and development of new biologic agents. Oncogene 22: 6629-6638.
43. Nies AT, (2007) The role of membrane transporters in drug delivery to brain tumors. Cancer Lett 254: 11-29.
44. Sarkadi B, Homolya L, Szakács G, Váradi A, (2006) Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. Physiol Rev 86: 1179-1236.